DLBCL Responds Well to Anti-CD19 CAR Therapy.

@article{2017DLBCLRW,
  title={DLBCL Responds Well to Anti-CD19 CAR Therapy.},
  author={},
  journal={Cancer discovery},
  year={2017},
  volume={7 3},
  pages={241-242}
}
According to an interim analysis of phase II data from a study of the anti-CD19 chimeric antigen receptor T-cell therapy KTE-C19, 76% of 51 patients with diffuse large B-cell lymphoma responded to the treatment; 47% had a complete response. After 3 months, 33% continued to experience a complete response.